Leadership
-
You want to wake up each morning, more capable than you were the day before. But eventually, our existence becomes constrained by time. Gordian imagines a life limited only by our imagination rather than by our physiology. We produce medicines that allow each of us to look forward to getting old. We are creating what all of us are running out of: time.
Francisco LePortCEO 
-
Most major diseases are driven by aging, but drug discovery largely ignores aging biology. This complex biology is only properly modeled in scarce animals that have aged and developed disease over time, and testing in these models at scale is only possible with Gordian’s technologies. Testing every therapy in the setting that most closely resembles human patients improves the odds of clinical success.
Martin Borch JensenCSO 
Management team
-
Chris Towne VP, Preclinical Research and Gene Therapy Towny’s long career in AAV gene therapy took him from Australia to EPFL and Stanford. He oversees preclinical gene therapy at Gordian.
-
Bharath Kumandan VP, Operations Bharath oversees everything from finding new Gors to our lab operations. He joins us with experience from Aligos Tx, J&J, and Alios Biopharma.
-
Neety Sahu Head of Osteoarthritis Biology Neety is leading Gordian’s OA discovery program, after an academic career in orthopedic medicine.
-
Vishwa Sontake Head of Lung Biology Vishwa has been attacking pulmonary fibrosis from every biological angle, and now leads our IPF discovery program.
-
Joanne Hsieh Head of Liver Biology Joanne is our resident NASH aficionado who leads our Liver Program and is on a mission to make the liver healthier. She comes to us from Columbia University where she studied gastrointestinal metabolism.
-
Naoto Muraoka Head of Cardiac Biology Naoto leads our heart program and is an expert in all things HFpEF. He comes to us from University of Washington where he was an acting instructor. With both a Phd and MD focusing on cardiology/cardiovascular disease he has valuable experience to help us push our heart program forward.
Get to know the diverse and extraordinary Gordian team
Advisory Council
-
Scott Friedman Icahn School of Medicine Advisor, Liver Disease, Clinical and Preclinical
-
Toby Maher USC & Imperial Advisor, Pulmonary Fibrosis, Clinical and Preclinical
-
Sanjiv Shah Northwestern Advisor, Heart Failure, Clinical
-
David Kass Johns Hopkins CardioScience Advisor, Heart Failure, Clinical and Preclinical
-
David Hunter University of Sydney Advisor, Osteoarthritis, Clinical
-
Dominic Grün Max Planck Freiburg Advisor, Single-cell informatics
-
Randy Platt ETH Zurich Advisor, Functional Genomics
-
Alexander III Macedon Advisor, Global Scaling
-
Laura Deming Investor & Board Member Managing Partner, Longevity Fund
-
Thomas Ebeling Investor CEO at Novartis (1998 – 2008), Supervisory Board Member at Bayer
-
Edward Lanphier Investor Founder and CEO at Sangamo Therapeutics (1995 – 2016)
-
Jeff Dean Investor Google Senior Fellow, SVP of Research and Health, Head of Google AI
Investors
Join the team
We are on a mission to cure age-related disease, allowing people to lead longer, healthier lives and wake up more capable than the day before.